https://www.selleckchem.com/pr....oducts/crenolanib-cp
come of patients with SUD, and the upcoming clinical trials involving CBD endorse the relevance of this review.Background The drug 5-aminosalicylic acid (5-ASA) is the first-line therapy for the treatment of patients with mild-to-moderate ulcerative colitis (UC). However, in some cases, 5-ASA cannot achieve the desired therapeutic effects. Therefore, patients have to undergo therapies that include corticosteroids, monoclonal antibodies or immunosuppressants, which are expensive and may be accompanied by significant side eff
Like
Comment
Share
